New blood test may help Fine-Tune diabetes treatment faster

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 20-70 years of age * newly diagnosed T2DM or duration of T2DM less than 1 year and without anti-diabetic medications for 3 months prior to screening * HbA1c ≥7.5% and \<10.5% Exclusion Criteria: * Requiring treatment of proliferative retinopathy, maculopathy, painful diabetic neuropathy, diabetic foot, diabetic ketoacidosis, or hyperglycemic hyperosmolar status in recent 3 months prior to screening. * The following history or conditions in recent 6 months prior to screening: (i) decompensated cardiac insufficiency (NYHA class III or IV); (ii)myocardial infarction, coronary artery bypass grafting or coronary stent implantation; (iii) uncontrolled severe arrhythmia and is not suitable to participate in this study evaluated by the investigator; (iv) hemorrhagic stroke or ischemic stroke and is not suitable to participate in this study evaluated by the investigator. * Laboratory indicators meet one of the following criteria: (i) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3× upper limit of normal(ULN); (ii) total bilirubin \> 2× ULN; (iii) hemoglobin \<100g/L; (iv)total protein \<60g/L; (v)albumin \<30g/L; (vi) glomerular filtration rate(eGFR)\<60 ml min-1 per 1.73 m2. * Thalassemia, hemolytic anemia and other diseases that may cause erythrocyte instability and affect the measurement of HbA1c. * Uncontrolled thyroid dysfunction. * Systemic corticosteroids treatment in recent 1 month prior to screening (exception of inhalation or local external treatment). * Pregnancy or lactating. * Two or more episodes of severe hypoglycemia in recent 1 year prior to screening. * Patient who need to initiate treatment with sulfonylureas, glinides, insulin or insulin analogues evaluated by the investigators. * Patient is being treated with calcium dobesilate or has a disease requiring calcium dobesilate treatment, or may be treated with calcium dobesilate in the near future evaluated by the investigators. * Patients considered unsuitable for observation by investigators.